
CQC’s new primary care framework: What GP practices should do now
CQC is retiring its single assessment framework for a primary care specific model from late 2026. Here's what's changing for GP practices, and what to do now.
Glossary
EBITDA stands for earnings before interest, tax, depreciation, and amortisation. It is a financial performance measure that reflects a company’s operating profitability by excluding financing costs, tax expenses, and non-cash accounting charges related to asset depreciation and amortisation.
EBITDA is a widely used financial metric that focuses on the earnings generated from a company’s core operations before the effects of financing structure, taxation, and certain accounting adjustments. By removing these factors, EBITDA provides a simplified view of operating performance.
The metric is commonly used by lenders, investors, and advisers when assessing a company’s financial position, particularly in lending arrangements, refinancing discussions, and business valuations. Because it excludes interest and tax costs, EBITDA allows comparisons between businesses with different capital structures or tax environments.
EBITDA is also frequently used in financial ratios such as debt-to-EBITDA and interest coverage ratios, which help lenders evaluate leverage levels and repayment capacity. In valuation analysis, EBITDA is often used in earnings-based valuation models where company value is estimated by applying industry earnings multiples.
In the UK, EBITDA is typically derived from financial information contained in statutory accounts prepared under accounting frameworks such as FRS 102 or IFRS, although the metric itself is not defined within those standards.
Key characteristics of EBITDA include the following:
EBITDA is typically calculated through the following steps:
A UK services company reports operating profit of £900,000. Depreciation and amortisation expenses total £100,000. Adding these non-cash expenses back to operating profit results in EBITDA of £1 million. This figure may be used by lenders when assessing leverage or covenant compliance.
EBITDA does not represent actual cash flow because it excludes changes in working capital and capital expenditure.
EBITDA is not defined within accounting standards and may vary between companies depending on calculation methods.
EBITDA does not reflect financing costs, which may be significant for highly leveraged businesses.
EBITDA indicates the level of earnings generated from a company’s core operations before the impact of financing costs, tax obligations, and non-cash accounting adjustments. It is commonly used to evaluate operating performance and compare businesses with different capital structures.
EBITDA and gross profit measure different aspects of financial performance. Gross profit reflects revenue after deducting direct costs of goods or services, while EBITDA considers operating expenses and adds back depreciation and amortisation.
EBITDA is used because it focuses on operating earnings and removes factors such as financing structure and taxation. This allows lenders and investors to compare companies more easily and assess operating performance in lending and valuation analysis.
EBITDA excludes capital expenditure, working capital changes, and financing costs. As a result, it does not fully represent the cash required to operate and maintain a business.
EBITDA is frequently used in valuation models where a company’s value is estimated by applying an earnings multiple to EBITDA. This approach is common in mergers and acquisitions and corporate finance analysis.
We always recommend that you seek advice from a suitably qualified adviser before taking any action. The information in this glossary entry only serves as a guide and no responsibility for loss occasioned by any person acting or refraining from action as a result of this material can be accepted by the authors or the firm.
Contact us today to find out more about how we can help you

CQC is retiring its single assessment framework for a primary care specific model from late 2026. Here's what's changing for GP practices, and what to do now.

How Price Bailey supports NRG Therapeutics with investor-led audit and governance advice as it transitions from discovery-stage research to clinical development...

Stay up-to-date with the data and stories emerging from UK valuations.

Tax Investigations Partner, Andrew Park, provides a round up of the most recent and significant contentious tax news. Read more here...